ABSTRACT
Objective:To explore the effects of hemodialysis combined with hemoperfusion on parathyroid hormone in elderly patients with renal bone disease.Methods:A total of 160 elderly patients with renal bone disease treated in our hospital between March 2020 and March 2021 were recruited as research subjects and divided into an observation group and a control group, with 80 people in each group.The control group was given routine hemodialysis treatment, 3 times a week.The observation group was treated with hemoperfusion, twice a month, in addition to treatment given to the control group.After continuous dialysis and hemoperfusion treatment for 6 months, the clinical efficacy, serum calcium, serum phosphorus, total parathyroid hormone, renal function indexes, bone metabolism indexes and the incidence of adverse reactions in the two groups were statistically analyzed.Results:The overall rate of effectiveness in the observation group(92.5%, 74 cases)was higher than that in the control group(81.3%, 65 cases), and the difference was statistically significant( χ2=6.699, P=0.035). After treatment, the level of serum calcium in the observation group was higher than that in the control group, while the levels of serum phosphorus and whole parathyroid hormone in the observation group were lower than those in the control group, and the differences were statistically significant( t=8.59, 8.96, 9.21, P=0.023, 0.001, 0.001); After treatment, the levels of β 2 microglobulin(β 2-MG)(BUN)in the observation group were lower than those in the control group, and the differences were statistically significant( t=5.29, P=0.036). As for values of bone metabolism indexes in the observation group after treatment, the levels of, N-MIDOs, β-Crossl and PINP were lower than those in the control group, and the differences were statistically significant( t=7.26, 6.16, 8.23; P=0.007, 0.018, 0.003). During treatment, the incidences of adverse reactions in the observation group and the control group were 20.00%(16/80)and 18.75%(15/80), respectively, with no statistical significance( χ2=0.725, P=0.615). Conclusions:Hemodialysis combined with hemoperfusion in the treatment of elderly patients with renal bone disease has a clear efficacy, can increase the level of serum calcium, reduce the levels of serum phosphorus and whole parathyroid hormone, and also can reduce the levels such as β 2-MG and bone metabolism indexes such as N-MIDOs, β-Crossl and PINP, indicating that this therapy can effectively improve calcium and phosphorus metabolism for elderly patients, delay the development of renal osteopathy, and should be recommended in clinical practice.